$GOSS News

Gossamer Bio Slides as $250M Financing Hinges on FDA Milestones

Gossamer Bio Enters Into Securities Purchase Agreement For Up to $250M Structured Private Placement

Piper Sandler Maintains Overweight on Gossamer Bio, Lowers Price Target to $4

Gossamer Bio Q2 EPS $(0.08) Beats $(0.12) Estimate, Sales $9.238M Beat $5.193M Estimate

Leerink Partners Upgrades Gossamer Bio to Outperform, Maintains Price Target to $1

Gossamer Bio Restructures Debt, Secures Full Control of Lead Drug Candidate

HC Wainwright & Co. Reiterates Buy on Gossamer Bio, Maintains $2 Price Target

Gossamer Bio, Inc. (GOSS) Discusses Reacquisition of Seralutinib Rights, Regulatory Progress and Capital Structure Updates Transcript

Gossamer Bio Secures Stockholders Approval For Proposals Related To Convertible Note Exchange And Reverse Stock Split; Reports $57M Cash Position

Gossamer Bio Advances Seralutinib Toward NDA In September 2026, Reacquires Global Rights To Seralutinib From Chiesi

Gossamer Bio (GOSS) Stock Fair Value Moves Lower After Mixed Analyst Target Changes

Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants

HC Wainwright & Co. Maintains Buy on Gossamer Bio, Lowers Price Target to $2

Gossamer Bio (GOSS) Stock Faces Mixed Analyst Target Changes On Funding Risk

Gossamer Bio Inc (GOSS) Q1 2026 Earnings Call Highlights: Strategic Debt Reduction and ...

Gossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes

Gossamer Bio Completes Debt Exchange, Converting $181M Of 2027 Notes Into New Secured Notes And Equity

Gossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes

How The Investment Story For Gossamer Bio (GOSS) Is Quietly Shifting Without New Analyst Signals

Gossamer Bio, Inc. Announces Extension of Early Tender Date for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes